To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Antiretroviral treatment … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Antiretroviral treatment for HIV infection: Swedish recommendations 2016.

Journal article
Authors Jaran Eriksen
Jan Albert
Anders Blaxhult
Christina Carlander
Leo Flamholc
Magnus Gisslén
Filip Josephson
Olof Karlström
Lars Navér
Veronica Svedhem
Aylin Yilmaz
Anders Sönnerborg
Published in Infectious diseases (London, England)
Volume 49
Issue 1
Pages 1-34
ISSN 2374-4243
Publication year 2017
Published at Institute of Biomedicine, Department of Infectious Medicine
Pages 1-34
Language en
Subject categories Infectious Medicine


The Swedish Medical Products Agency and the Swedish Reference Group for Antiviral Therapy (RAV) have jointly published recommendations for the treatment of HIV infection on seven previous occasions (2002, 2003, 2005, 2007, 2009, 2011 and 2014). In February 2016, an expert group under the guidance of RAV once more revised the guidelines. The most important updates in the present guidelines are as follows: Tenofovir alafenamide (TAF) has recently been registered. TAF has several advantages over tenofovir disoproxilfumarate (TDF) and is recommended instead of TDF in most cases. First-line treatment for previously untreated individuals includes dolutegravir, boosted darunavir or efavirenz with either abacavir/lamivudine or tenofovir (TDF/TAF)/emtricitabine. Pre-exposure prophylaxis (PrEP) is recommended for high-risk individuals. As in the case of the previous publication, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine ( ) ( Table 1 ). This document does not cover treatment of opportunistic infections and tumours. [Table: see text].

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?